START FREE TRIAL
Home Healthcare Baxter International Inc.

Baxter International Inc.

$19.00

SKU: BAX Category:

Description

Baxter International’s $50 Million Product Exit — Is Its Recovery Facing Another Test?

 

Baxter International Inc. reported third quarter 2026 results demonstrating modest progress within its ongoing turnaround efforts. The company posted approximately $3 billion in global sales, reflecting a 5% increase on both reported and organic bases, with growth broad-based across all divisions and geographies. Key contributors included Advanced Surgery, Drug Compounding, and Infusion Systems. Adjusted earnings per diluted share were $0.58, surpassing internal expectations but declining 16% year-over-year, primarily due to a higher effective tax rate compared to the prior year’s discrete tax benefits. Operationally, Baxter highlighted improvements in execution and quality metrics, such as an 8% increase in on-time shipments within Care & Connectivity Solutions and nearly 20% improvement in quality measures for Advanced Surgery. However, supply challenges persisted, particularly related to manufacturing at the Round Lake specialty injectable facility, prompting the discontinuation of cephalosporin product production.